Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Seelos Therapeutics Inc (SEEL)

Seelos Therapeutics Inc (SEEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Seelos Therapeutics Inc 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 USA

www.seelostherapeutics.com Employees: 16 P: 646-293-2100

Description:

Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.

Key Statistics

Overview:

Market Capitalization, $K 255
Enterprise Value, $K -3,505
Shares Outstanding, K 372
Annual Sales, $ 2,200 K
Annual Net Income, $ -37,880 K
Last Quarter Sales, $ 380 K
Last Quarter Net Income, $ 1,710 K
EBIT, $ -29,810 K
EBITDA, $ -28,970 K
60-Month Beta 1.94
% of Insider Shareholders 1.08%
% of Institutional Shareholders 23.37%
Float, K 368
% Float 98.92%
Short Volume Ratio 0.51

Growth:

1-Year Return -99.89%
3-Year Return -99.99%
5-Year Return -99.98%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 97.87%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.92 on 08/14/24
Next Earnings Date 11/12/24 [--]
Earnings Per Share ttm -1,099.95
EPS Growth vs. Prev Qtr 107.50%
EPS Growth vs. Prev Year -82.05%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-16 on 09/27/24

SEEL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -431.47%
Profit Margin % -1,721.82%
Debt/Equity 0.00
Price/Sales 0.12
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -133.95
Interest Coverage -472.50
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar